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PENILAIAN HASIL KLINIKAL PADA PESAKIT PEMFIBRILAN ATRIUM 
YANG MENERIMA WARFARIN UNTUK PENCEGAHAN STROK 
SEKUNDER DI KLINIK KEPATUHAN TERAPI UBAT-UBATAN DI 
HOSPITAL SERDANG DAN HOSPITAL SEREMBAN 
 
ABSTRAK 
 
Di Klinik Kepatuhan Terapi Ubat-ubatan (Warfarin-MTAC), ahli farmasi perlu 
memainkan peranan dalam pasukan kesihatan pelbagai disiplin untuk meningkatkan 
kepatuhan pesakit bagi mencapai matlamat terapi warfarin. Matlamat utama kajian ini adalah 
untuk menilai keberkesanan perundingan ahli farmasi dalam mencapai kualiti yang lebih 
baik dalam kawalan antikoagulasi. Ia juga bertujuan untuk mengenal pasti faktor-faktor yang 
menyumbang kepada kegagalan atau kejayaan untuk mencapai INR terapeutik. Suatu kajian 
prospektif telah dibuat di Warfarin-MTAC yang beroperasi di Unit Jantung di Hospital 
Serdang dan Hospital Tuanku Ja'afar Seremban pada tahun 2011. Seramai tiga ratus lima 
puluh dua pesakit yang didiagnosis dengan pemfibrilan atrium memenuhi kriteria kelayakan 
dan dipilih menggunakan teknik persampelan rawak. Pesakit terdiri daripada kaum Melayu, 
Cina dan India dengan purata umur 64.2 dan 64.6 tahun memiliki risiko strok kategori 
sederhana (skor CHADS2: 2.3±1.2 dan 2.7±1.3) untuk pesakit di Hospital Serdang dan 
Hospital Seremban. Kepatuhan pesakit terhadap terapi warfarin seperti yang dinasihatkan 
oleh ahli farmasi didapati menjadi faktor penyumbang kepada pencapaian kualiti yang baik 
dalam kawalan antikoagulasi (nisbah kebarangkalian: 53.3 dan 52.0, p < 0.05; CI = 95%) 
bagi pesakit di Hospital Serdang dan Seremban. Kawalan didapati mencapai prestasi yang 
baik dengan %TTR sebanyak (81.1+21.1) % dan (77.9+12.6) % untuk kedua-dua hospital. 
Kesimpulannya, untuk mengelakkan strok dan pengambilan warfarin yang berlebihan, serta 
memastikan perundingan yang berkesan dengan ahli farmasi, ahli farmasi perlulah memberi 
nasihat yang menyeluruh kepada pesakit pemfibrilan atrium yang menerima rawatan 
warfarin di Klinik Terapi Antikoagulasi dan menekankan keutamaan untuk terapi warfarin. 
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THE CLINICAL OUTCOME EVALUATION ON THE ATRIAL 
FIBRILLATION PATIENTS RECEIVING WARFARIN FOR SECONDARY 
STROKE PREVENTION IN THE MEDICATION THERAPY ADHERENCE 
CLINIC IN SERDANG AND SEREMBAN HOSPITALS 
  
ABSTRACT 
 
In the Warfarin-Medication Therapy Adherence Clinic (Warfarin-MTAC), 
pharmacists should play their role in the multidisciplinary health team to improve patients’ 
adherence in achieving the goal of warfarin therapy. The primary aim of this study is to 
evaluate the effectiveness of pharmacists’ consultation in order for atrial fibrillation (AF) 
patients receiving warfarin to achieve better quality of anticoagulation control. It also aims to 
identify the factors contributing to the failure or success of reaching the therapeutic INR. A 
prospective study was carried out in the Warfarin-MTAC that operated in the Cardiac Unit 
of Serdang and Seremban Hospitals in 2011. Three hundred and fifty-two AF-diagnosed 
patients were represented in the inclusion criteria, selected using the convenience sampling 
technique.  The patients consist of Malay, Chinese and Indian with the mean age of 64.2 and 
64.6 years old, and had the CHADS2 score of 2.3±1.2 and 2.7±1.3 for patients in Serdang 
and Seremban Hospitals, respectively. Patients’ adherence to warfarin therapy as had been 
guided by Pharmacist was found to be a factor that contributed to the achievement of good 
quality of anticoagulation control (Odds ratio: 53.3 and 52.0 at p < 0.05 and CI = 95% for 
those in Serdang and Seremban Hospitals respectively). The anticoagulation control 
achieved is ‘good’ with %TTR of (81.1 +21.1)%  and (77.9+12.6)% for both hospitals. As a 
conclusion, to prevent stroke and avoid overwarfarinization, and to ensure effective 
consultation with pharmacists, the pharmacists should provide comprehensive advice to 
patients with atrial fibrillation who are receiving warfarin treatment at the Anticoagulation 
Therapy Clinic and emphasize on the prioritized characteristics for the warfarin therapy. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Research Background. 
 
 1.1.1 The significance of anticoagulation therapy using warfarin with the 
involvement of pharmacists in collaborative multidiscipline health care 
practices. 
 
Warfarin therapy for patients with atrial fibrillation has been done to resonate 
with the consideration that warfarin is effective and inexpensive for secondary 
prevention against stroke. A care system for patients had been improved with the 
implementation of integrated and multidisciplinary services to control warfarin 
anticoagulation. Practically, there are many other aspects that have been constrained 
in the monitoring of warfarin treatment. In evaluating the effectiveness of warfarin 
therapy, the social characteristics of the patients cannot simply be ignored.  Even 
though it resulted in the lack of clarity of the causal answer, the extent of the 
socioeconomic status of the patients had influenced the risk of haemorrhage and 
other adverse outcomes (Cressman et al., 2015). 
 
Extra stringent monitoring is very much needed to be done in warfarin therapy 
for patients with atrial fibrillation because it may be able to prevent stroke without 
increasing the risk of bleeding. That outcome would be impossible to be achieved if 
the pre-existing risk factors are obeyed, regardless of the factors such as young age, 
those with less co-disorder, and those having low-risk factor to get stroke (Chishaki 
et al., 2015). 
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The practice of pharmacy has been improved including ambulatory care 
services. There is a global concern for pharmacists to build a model that aims to 
minimize side effects and optimize anticoagulation control (Louis et al., 2010). 
 
In Malaysia, the Medication Therapy Adherence Clinic (MTAC), a 
multidiscipline ambulatory care system for atrial fibrillation patients with warfarin 
therapy has been established since 2004. 
 
In Malaysia, all patients treated with warfarin anticoagulation have been 
integrally relocated in phases, in the MTAC clinic which is organized by the General 
Hospital in each state. All atrial fibrillation diagnosed patients who received warfarin 
treatment was referred to the clinic. 
 
At the beginning of this research, several surveys were conducted in a number 
of existing government health clinics around the hospital where warfarin MTAC are 
located. There was no patient receiving warfarin therapy there because all of them 
had been referred to the hospital, and it is also due to the fact that services such as 
warfarin MTAC had not been established yet. 
 
There have been widely published papers or reports on warfarin therapy but the 
study on the evaluation of care management is irrefutably scarce. Most of the 
researchers were interested to focus their study on the effect of care management to 
control the anticoagulation therapy. However, the evaluation of the effectiveness of 
warfarin in patients with atrial fibrillation is supposed to be examined from several 
clinical and management aspects. A very complex set-up through multidisciplinary 
care may become an important consideration for the improvement of the 
3 
 
effectiveness of warfarin anticoagulation service. This is certainly in accordance with 
the implication of the existing guidelines (Alpert, 2010). 
 
The existing guideline is lengthy for the doctors, hence time-consuming for 
them to understand. It is also difficult for them to use and the approach used is less 
comfortable for the patients. The rigid guidelines and frequent monitoring therapy 
were not favoured by both the physician and patient. Even doctors sometimes require 
specific guidelines which include patients with specific criteria (Alpert, 2010). 
 
How pharmacists should play their role is also included in the evaluation. In 
real practice, an evaluation of the human factors that include the pharmacists‟ 
involvement in the service should be determined as the variables or indicators that 
may affect the outcome of the therapy. In this study, those factors will be 
investigated as variables in achieving clinical outcomes in the prevention of stroke in 
patients receiving warfarin therapy. 
 
 1.1.2 The challenge for pharmacists in achieving the therapeutic goal of 
warfarin therapy in patients with atrial fibrillation. 
 
The therapeutic goals of warfarin therapy in patients with atrial fibrillation are 
to minimize the symptoms and to prevent thromboembolic events such as death, 
stroke, and hospitalizations. It also aims to increase the quality of life and exercise 
capacity, and to reduce the left ventricular dysfunction. The pharmacologic treatment 
for atrial fibrillation with antithrombotic agent includes anticoagulation therapy with 
vitamin K antagonist, antiplatelet therapy, vitamin K antagonist combined with anti 
platelet and/or other antithrombotic drug regimens (Camm et al., 2010). 
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To achieve a better outcome, a number of anticoagulation managed care had 
been arranged by pharmacist in collaboration with other health professionals. In fact, 
a lot of publications have revealed that patients with atrial fibrillation had been found 
to be undertreated in warfarin therapy for stroke prophylaxis. It was proven that 
patients who are at high risk of stroke were significantly associated with the 
suboptimal warfarin treatment (Nieuwlaat et al., 2010).  
 
The administration of warfarin should be controlled in order to individualize 
dose regimen, and this may result in the appropriate therapeutic effect of 
anticoagulation. Underutilization of warfarin prescribed to young and elderly patients 
may cause the international normalized ratio (INR) to not be able to reach the target 
range. For those patients, having non-therapeutic INR was strongly associated with 
stroke risk, arterial thromboembolism and intracranial bleeding (Walker & Bennett, 
2008).  
 
The investigation on the decision-making between physicians and patients that 
resulted in a dichotomous opinion was reported by Xuereb et al. (2012). In the 
situation where intensive communication between physicians and patients should 
exist, “patient education” became critical to be achieved. Through this 
communication, educational intervention can meet the needs and concerns to achieve 
better patient outcome as expected. 
 
Pharmacists involved in a healthcare team should play an intensive role in 
providing information as suggested by McCabe et al. (2008). New trends in 
antithrombotic therapy should not allow patients to self-manage the therapy. The 
booklet given by health providers to patients does not guarantee complete guidance 
5 
 
because patients might be unable to understand the efficacy and safety of warfarin. 
Furthermore, if patients could not identify warfarin-related ADR, it is highly not 
recommended for them to perform self-management and monitoring. 
 
Although patients have received warfarin booklets, they may still require 
educational intervention to improve their knowledge and perceptions on the 
treatment of atrial fibrillation with anticoagulation. They should improve their 
knowledge on the risks of using warfarin (Lane et al., 2006). 
 
Pharmacists‟ involvement in anticoagulation clinics to encourage the 
application of evidence-based therapy is important. Pharmacists need to share their 
knowledge regarding correct warfarin regimen. If the prescribed dose results in lower 
than minimum response of anticoagulation, it may cause thromboembolism, while 
excessive dose will probably cause bleeding. Thus, this means that the spread of 
knowledge to patients receiving warfarin must be encouraged. To gain this 
knowledge, patients should get help from pharmacists and other healthcare 
professionals. From the pharmacist, patients may get help to improve compliance, 
and from the physician, patients need help to achieve the goal therapy. Therefore, the 
pharmacists involved should share the knowledge on appropriate dose management 
with the physicians. In this interrelationship, Kakkar and Kaur (2004) suggested that 
good patients‟ adherence to warfarin guidelines is compulsory.  
 
The significant gaps in stroke-related health literacy existing among high risk 
patients taking warfarin are likely to represent the mismatches of ways in which 
clinicians educate patients on what they must learn. This gap resists the improvement 
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of health communication about stroke-related knowledge between patients and health 
clinicians (Fang et al., 2009). 
 
Interactive patients‟ education model by means of audiovisual communication 
between physicians and patients has been tested, where it gave different results in 
warfarin-related knowledge, and belief in the importance of INR testing. Mazor et al. 
(2007) concluded the investigation by stating that patients with oral anticoagulant 
therapy would benefit from educational efforts periodically to reinforce the 
importance of information about drug safety, both during and after the education 
continuously takes place. 
 
Warfarin is effective for stroke prophylaction in patients with atrial fibrillation, 
as measured proportionally to the predictor, which is the time in target range (TTR). 
However, warfarin practice managed by primary care physicians is more often based 
on their own experiences. Evidence-based methods for warfarin maintenance dose 
are underused by primary care physicians (Nieuwlaat et al., 2010).  
 
Characteristics of atrial fibrillation patients aged more than 80 years old 
include having problems in attending outpatient anticoagulant monitoring service and 
in self-managing their own warfarin dose, being unable to identify bleeding signs and 
symptoms, bruising, falling, taking concomitantly interacting medication, showing 
erratic INR readings, necessitating emergency department assessment for vitamin K-
reversal, having the difficulty to make or even missed appointments.  There is a need 
to increase the resources for monitoring in the community setting, for instance home 
visits, portable INR monitoring devices and dose adjustments (Tan et al., 2012).  
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 There are some herbs and supplements that have been reported to interact with 
warfarin as Cinnamomum sp, Ginko, Allium sp, Zingiber sp, green tea, St. John's 
wort, Curcuma sp, saw palmetto, Valeriana officinalis, milk thistle and Echinacea. 
These findings help healthcare practitioners to monitor consumption of herbs and 
supplements for the safety of patients receiving warfarin (Colalto, 2010).  
 
Pharmacists should be concerned about the medications or herbal medicines 
taken by the patients‟ own initiative that might not accurately reflect its contents as 
mentioned on the label. The renal toxic agent contained in pharmaceuticals product, 
non-steroid anti inflammatory drugs (NSAIDs), laxatives, corticosteroids and highly 
heavy metal contaminations and some other herbs that may interfere with the platelet 
functions should become part of the information that needs to be conveyed to 
patients (Fugh-Berman, 2000). 
 
 1.1.3 The growing population of patients with atrial fibrillation. 
 
The number of patient with atrial fibrillation (AF) is seemingly increasing and 
spreading rapidly. Atrial fibrillation is a type of disease that disrupts the rate and 
heart rhythm. The disruption of the rate and rhythm of the heart, known as 
arrhythmia, may be investigated by electrocardiogram (ECG). The abnormalities of 
rate and heart rhythm in atrial fibrillation patients are due to impaired mechanical 
function of the atrium termed supraventricular tachycardia (Fuster et al., 2006a). 
 
The population of patients with atrial fibrillation has increased, along with the 
increasing underlying risk factors and its severities. The risk factors of atrial 
fibrillation include older age, male, high blood pressure, ischemic heart disease, 
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valvular heart disease, diabetes mellitus, and history of thromboembolic event, 
obesity, hyperthyroidism, alcoholism and cigarette smoking (Nguyen et al., 2013). 
The increased population of patients with atrial fibrillation is likely due to other risk 
factors that include problem of respiratory system, dyslipidemia, renal insufficiency 
and coagulopathy, dementia, and history of gastrointestinal bleeding. According to 
Walker & Bennett (2008), cardiovascular disease is most likely the co-morbidity 
factor that contributes to the prevalence of atrial fibrillation. 
 
The population of atrial fibrillation patients increased with the rise of the 
number of patients that may be subjected to heart failure. Heart failure will 
exacerbate the atrial fibrillation, or vice versa.  In patients with heart failure, the left 
ventricular function will be impaired, hence the left ventricle ejection fraction 
(LVEF) will be reduced. Maisel and Stevenson (2003) had reviewed the association 
between the reduction of LVEF with the prognosis of atrial fibrillation. The 
prevalence of patients having the symptoms of severe heart failure associated with 
atrial fibrillation increased twofolds, compared to patients with moderate heart 
failure.  
 
The prevalence of atrial fibrillation increases with age of patients. Among the 
elderly, congestive heart failure is associated with the history of myocardial 
infection. An equal prevalence of atrial fibrillation was found between the elderly 
with or without the preserved left ventricular function. Hospital admission is an 
indication of atrial fibrillation prevalence. Maisel and Stevenson (2003) revealed that 
hospital admission of atrial fibrillation patients with left ventricle ejection fraction 
less than 40% was higher compared to that of patients aged more than 70 years old. 
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Freestone et al. (2003) reported that the prevalence of atrial fibrillation patients 
in 2003 recorded in Kuala Lumpur General Hospital in Malaysia was 2.8%. This 
report indicates that the rise of atrial fibrillation is newly diagnosed. This information 
is almost similar to the previous report from the investigation done by Choy et al. 
(1993) showing that the atrial fibrillation population in Malaysia increase with the 
number of cardiovascular patients, especially those suffering from hypertension and 
ischemic heart disease. 
 
Regionally, Asia contributes to the increment in prevalence of atrial fibrillation 
patients as reported by Chiang et al. (2012). In 2045, the number of patients with 
atrial fibrillation in China is projected to increase dramatically from 10 million to 25 
million patients (Ma & Qi, 2009).   
 
Stroke prevalence is said to increase the mortality rate of patients with atrial 
fibrillation. It was recorded that patients with atrial fibrillation who experienced 
thromboembolic event constituted the top leading cause of death in Asian countries. 
The death rates approximately ranged from 11.9 per 100,000 in Malaysia, 10.9 per 
100,000 in Thailand and up to 54.2 per 100,000 in Singapore as reported by Merican 
et al. in 2006. In several countries in Asia such as China, Japan, Singapore, Malaysia 
and Taiwan, the prevalence of stroke related to atrial fibrillation is found to be varied 
with the range of 13.0%–15.4% (Guo et al., 2012).  
 
Some efforts to reduce the prevalence rate of stroke that complicate patients 
with atrial fibrillation have been conducted. A total of 40,000 patients with atrial 
fibrillation in Taiwan who visited the hospital and three clinics during the two-year 
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period had been investigated by Lin et al. (2008). Patients were recommended to be 
prescribed with anticoagulants but it was proven that as much as 75% of them were 
not treated with antithrombotic therapy appropriately. 
 
The growing number of patients with atrial fibrillation in Asian countries 
will rise as predicted by Ryder and Benjamin (1999) due to the change of age 
composition in which the number of elderly people increases. The prevalence of 
atrial fibrillation in Hong Kong is 1.3% for patients in the age group of 60–94 years.  
 
In 2012, Suarez et al. reported that hospital admission of heart failure patients 
with atrial fibrillation in the Asia Pacific region and Latin America countries had 
increased. These countries include Mexico, Australia, Hong Kong, Indonesia, 
Malaysia, Philipines, Singapore, Taiwan, Thailand and Brazil. Additionally, previous 
study conducted by Omar et al. (2011) supported that the prevalence of atrial 
fibrillation in Asia is said to be parallel with increasing morbidity rate and the 
number of patients who are at risk of cardiovascular events.  
 
Factors contributing to atrial fibrillation were assessed in the Framingham 
Heart Study based on age, gender and racial background. The prevalence of atrial 
fibrillation in men was threefold in three decades from 3.2% to 9.1% and was almost 
doubled in women. The incidence of atrial fibrillation increases sharply with age. 
The prevalence of atrial fibrillation was also contributed by race. In Blacks and Afro-
Caribbean, atrial fibrillations increase as patients‟ hypertension increases; in South 
Asian population, atrial fibrillations increase with ischemic heart disease; and in 
Ethiopia it increases with rheumatic heart disease (Ryder & Benjamin, 1999). 
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In the United States over the past three decades, the number of adults who have 
atrial fibrillations increased by 50% more than the number of the elderly (more than 
80 years old). It is estimated that the overall prevalence of atrial fibrillation is 3 in 
1000 persons per year in men and 2 in 1000 persons per year in women aged 55–64 
years old (Hersi & Wyse., 2005). 
 
 1.1.4 The pathophysiology, clinical significance and treatment option of 
atrial fibrillation. 
.   
  1.1.4(a) The pathophysiology of atrial fibrillation. 
 
Atrial fibrillation is defined as a deterioration of atrial mechanical function 
caused by uncoordinated atrial function characterized as supraventricular 
tachyarrhythmia. Clinically, atrial fibrillation is presented as newly diagnosed atrial 
fibrillation that is considered to have been presented for the first time and pre-
existing atrial fibrillation that is presented on the follow-up encounter (Fuster et al., 
2006a).  
 
The morphology of heart is changed in atrial fibrillation patients. The inner 
layers of atrial myocardium are altered. It may be caused either by heart disease 
(coronary heart disease, high blood pressure or aortic stenosis) or aging process (such 
as fibrosis). The morphologic change may lead to abnormal electrophysiological 
properties of the heart. This abnormality is responsible for the exacerbation of atrial 
fibrillation and extends to the severe state of atrial fibrillation, or commonly referred 
as a concept of “atrial fibrillation begets atrial fibrillation” (Lee & Chen, 2008). 
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Although heart disease may cause atrial fibrillation, this mechanism is unclear, 
even though the predisposition of heart failure is suggested as a condition that is 
responsible for the change of the heart, especially the atrial. The morphologic change 
occurs concomitantly along with the functional change of heart in atrial fibrillation, 
which may be described as below: 
 
 a. The change in neurohormonal activation due to the stimulation of the renin-
angiotensin-aldosterone system. 
 b. The change in the electrophysiological activity that is basically referred as the 
change in the parameter of the heart function, and it is called the atrial 
refractory period. In atrial fibrillation, the atrial refractory period is reduced as 
the mechanical function decreases. The decrease in the atrial effective 
refractory period (ERP) will cause irregular atrial repolarisation response. This 
change will then deteriorate the morphology (remodelling) of the heart and in 
turn, the rate and rhythm of the heart will interfere. 
 c. The change of the hemodynamic properties such as the pressure and volume of 
blood that may be due to the change of neurohormonal stimulation, or vice 
versa (Maisel & Stevenson, 2003). 
 
The change in the heart for patients with heart failure is markedly influenced 
by the progressions of atrial fibrillation or the mechanism might occur in opposite to 
exacerbate the failure. The mechanism is proposed by Maisel and Stevenson (2003) 
where it is termed as “heart failure begets atrial fibrillation”, or vice versa.   
 
Atrial fibrillation is said to be a structural heart disease that is often associated 
with the diseases that interfere with the function of the heart (Hersi & Wyse, 2005). 
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It is caused by the presence of both atrial electrical remodelling – contractile or 
structural – which will be clearly visible when the period of atrial fibrillation effect is 
long term. Electrical remodelling is characterized by a shortening of the atrial 
refractory period. Thorough clinical evaluation of patients who are presented with 
the risk factors that include hypertension, congestive heart failure, ischemic 
cardiomyopathy, valvular (rheumatic) heart disease, diabetes mellitus, 
hyperthyroidism, obesity, and obstructive sleep apnoea can facilitate early diagnosis 
of atrial fibrillation (Eagle et al., 2011). 
 
The onset of atrial fibrillation may be classified based on the mechanism and 
its duration. European Heart Rhythm has classified it as paroxysmal, persistent or 
permanent atrial fibrillation. Paroxysmal atrial fibrillation episodes generally last for 
less than 24 hours but sometimes up to seven days, intermittently, repetitively and 
that it self-subsides (Fuster et al., 2006b). Paroxysmal atrial fibrillation constitutes 
35% to 65% of all cases of atrial fibrillation. It is more common in men and in 
younger patients than is chronic atrial fibrillation (Masoudi & Goldschlager, 1997). 
Persistent atrial fibrillation episode lasts more than seven days and requires its 
termination, either pharmacologically or electrically, or self-termination, but it can be 
effectively cardioverted to sinus rhythm. Sustained for a period of time, physical and 
molecular changes in the electrical and structural properties of the atria 
(“remodelling”) occur and facilitate the conversion from transient to persistent atrial 
fibrillation (Peters et al., 2002). Permanent atrial fibrillation has long-standing, 
continuous episodes, and it cannot be terminated by cardioversion. It can be 
terminated only for brief intervals, and it may lasts longer than a year without the 
cardioversion. Acute episode of atrial fibrillation lasts with its onset usually within 
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48 hours. Chronic atrial fibrillation requires a continuous clinical course similar to 
persistent and permanent atrial fibrillation (Peters et al., 2002).  
 
Recurrent atrial fibrillation is a term used to describe that at least twice of 
paroxysmal or persistent episodes can occur. The episodes of recurrence last more 
than 30 seconds. Reversible causes such as cardiac surgery, myocardiac infarction, 
pulmonary embolism, myocarditis or thyroid disease are excluded. If the reversible 
causes exist, the treatment of these underlying causes simultaneously with atrial 
fibrillation episodes will eliminate the arrhythmia, and the rhythm management will 
take longer duration (Hersi & Wyse, 2005).  
 
In the absence of the predisposing factors, “lone atrial fibrillation” is used to 
describe younger patients (less than 60 years old) who have atrial fibrillation. The 
baseline ECG does not experience or recognize any symptoms. The term should be 
used to describe those patients with atrial fibrillation who do not have other co-
existing valvular or structural heart disease and diabetes (Masoudi & Goldschlager, 
1997). 
 
  1.1.4(b) The clinical significance of atrial fibrillation. 
 
The symptom of atrial fibrillation may be presented with the onset of 
palpitations, chest pain, dyspnoea, fatigue, dizziness, light-headedness, syncope, and 
polyuria. Loss of normal atrial contractility is the sign that affects the 
synchronization of ventricle at the atrioventricular (AV) node. Heartbeat rate 
irregularity and rapid ventricular response are typical signs found in atrial 
fibrillation. Each sign may contribute to variable degrees of atrial fibrillation 
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manifestation (Peters et al., 2002). Atrial fibrillation patients are called asymptomatic 
if they do not present any of the symptoms.  
 
The diagnosis of atrial fibrillation is supported by evidence of oscillation or 
fibrillatory wave in the electrocardiogram, which seems to be regularly inconsistent 
in shape, amplitude and time interval (Fuster et al., 2006a). 
 
Atrial fibrillation is commonly presented with underlying co-morbidities such 
as cardiovascular disease. In the circumstances, atrial fibrillation will aggravate the 
risk of presenting thromboembolic event or ischemic stroke, as revealed by The 
Reduction of Atherothrombosis for Continued Health (REACH) Registry (Ohman et 
al., 2006).  
 
As defined by Malaysian Guideline, stroke is “a clinical syndrome 
characterized by rapidly developing clinical symptoms and/or signs of focal, and at 
times global, loss of cerebral function, with onset lasting more than 24 hours or 
leading to death, without apparent cause other than that of vascular origin” (Merican 
et.al., 2006).
 
  
 
Stroke is a condition that has higher mortality and morbidity especially in those 
with atrial fibrillation risk factors such as rheumatic heart disease. Atrial fibrillation 
in an individual who has rheumatic heart disease of the mitral valve or history of 
valve replacement is referred as non-valvular atrial fibrillation or NVAF (Fang et al., 
2007).     
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  1.1.4(c) Treatment options for atrial fibrillation. 
 
The treatment options for atrial fibrillation aim to solve two major problems: 
a. To treat the primary problems related to structural and functional abnormalities of 
the heart. It is focused on restoring the heart function to the normal sinus rhythm 
and to control the rate of the heartbeat.  
b. To protect the heart which extends to precipitating the worst onset caused by the 
factors that result in an abnormal condition that is called thromboembolism or 
stroke. Some of the researchers used the term „secondary stroke prevention‟ as the 
treatment of this atrial fibrillation does not seek to resolve the condition caused by 
the primary problems. Hirsh et al. (2003) revealed that in the European Atrial 
Fibrillation Trial (EAFT), anticoagulation therapy is recommended as a treatment 
for secondary stroke unless otherwise contraindicated. 
 
The paradigm of atrial fibrillation treatment is shifting, from the conventional 
focus of achieving heart rate control or rhythm restoration, to the use of the safest 
agents that potentially reduce patients‟ symptoms and improve their quality of life 
and cardiovascular outcomes. No new anti atrial fibrillation drugs have been 
introduced for decades. The existing pharmacotherapeutic modalities have 
potentially resulted in serious side effects as well as suboptimal efficacy in 
converting and maintaining normal sinus rhythm and preventing the recurrence 
(Omar et al., 2011). 
 
Digoxin in combination with β-blockers or calcium channel blockers is 
recommended as the first-line therapy in elderly patients with atrial fibrillation, 
because of its effectiveness in controlling ventricular rates and avoiding the toxicity 
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of digoxin single therapy (Lee & Chen, 2008). Olshansky et al. (2004) also reported 
in their investigation that an adequate rate control can be achieved either alone with 
the β-blocker only, calcium channel blocker, digoxin or each combination with 
digoxin. Among these combinations with digoxin, β-blocker is stronger in 
controlling the ventricular rate compared to calcium channel blocker. 
 
Direct current cardioversion by means of the administration of antiarrhythmic 
drug is beneficial for patients with chronic atrial fibrillation in order to reduce, to 
make less frequent and to shorten the duration of the antiarrhythmia. Antiarrhythmic 
drug administration may be selected based on the Vaughan Williams class IA, e.g. 
disopyramide and procainamide, class IC (flecainide, propafenone), and class III 
such as sotalol, amiodarone, ibutilide, and dofetilide (Slavik‟s et al., 2001). 
 
Pharmacologic treatment of ventricular rate control is recommended for 
asymptomatic atrial fibrillation patients who have been experiencing the urgency to 
restore sinus rhythm, for those with persistent atrial fibrillation in which it is not 
possible for antiarrhythmia drug to restore sinus rhythm or for patients who have 
worse symptoms with antiarrhythmic drug.  The maintenance of sinus rhythm is 
recommended if these conditions do not exist (Prystowsky et al., 2000). 
 
The pharmacologic treatment for prevention for patients with atrial fibrillation 
may be performed by the maintenance of the sinus rhythm. Dronedarone or 
amiodarone are recommended for the conversion to sinus rhythm, thereby reducing 
the recurrence period. Amiodarone is more likely efficacious than dronedarone. 
Dronedarone administration is contraindicated with the use of CYP3A4 inhibitors 
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such as macrolide antibiotics and diltiazem due to the potentiation of dronedarone‟s 
response (Wann et al., 2011). 
 
The AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm 
Management) recommended amiodarone as an antiarrhythmic drug for elderly 
patients with atrial fibrillation. Amiodarone is safe in preventing attacks (recurrent) 
and it facilitates electrical cardioversion in elderly patients with paroxysmal atrial 
fibrillation (Sellers & Newby, 2011).  
 
The management of atrial fibrillation specially prioritized the prevention of 
thromboembolism and the control of heart rate and rhythm. Pharmacological rate 
control has been shown to produce similar results compared with pharmacological 
restoration of sinus rhythm. The therapy of atrial fibrillation should be initiated for 
elderly patients. The priority in the pharmacologic treatment of atrial fibrillation is to 
prevent thromboembolism and control heart rate and rhythm, including for elderly 
patients. However, the administration of anticoagulants is still given for secondary 
prevention against stroke in elderly patients. Therefore, elderly patients are 
particularly at risk of bleeding and experiencing cognitive dysfunction, and 
functional disorders as well as highly at risk of fall, hence close monitoring needs to 
be performed (Fang et al., 2007). 
 
 
 Men were more likely to have ischemic heart disease than women. The 
prevalence of morbidity related to atrial fibrillation is higher in women; therefore 
women are more likely to experience symptomatic attacks than men. Atrial 
fibrillation therapy with antiarrhythmic drug, amiodarone, increased the risk of 
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bradyarrhythmia more in women than in men. Hormonal fluctuations should be 
considered in selecting antiarrhythmic drugs for premenopausal women. The risk of 
morbidity related to atrial fibrillation is significantly higher in women than in men. 
Women who experienced longer symptomatic episodes and frequent recurrences 
were more likely to have lower Quality of Life (QoL). Therefore women were more 
likely to withhold oral anticoagulation despite being at risk. This evidence suggests 
that anticoagulation is underutilized in women aged more than 75 years, a subgroup 
that has particularly high thromboembolic risk (Volgman et al., 2009). 
 
Rate control is more reasonable for the initial treatment of older patients to 
minimize the symptoms and to avoid tachycardia-induced cardiomyopathy rather 
than rhythm maintenance as the elderly tend to have higher mortality. 
Antiarrhythmic drugs are beneficial to maintain sinus rhythm in the subgroup that 
remains symptomatic even though the rate control is effective. In elderly patients 
who have reduced renal and hepatic clearance, the risk for proarrhythmia and drug 
interactions increase when using antiarrhythmic drugs, and there is the highest 
likelihood of increase in polypharmacy (Eagle et al., 2011). 
 
 1.1.5 The pharmacologic treatment for stroke prevention. 
 
The pharmacologic treatment for stroke prevention focused on antithrombotic 
that are anticoagulant and antiplatelet. In the AFASAK study investigated by 
Peterson et al. (1989), warfarin was recommended as an anticoagulant because it is 
more effective to prevent stroke/TIA and thromboembolic events in patients with 
non-rheumatoid chronic atrial fibrillation than low-dose aspirin as antiplatelet or 
placebo. 
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Various studies had indicated an association between atrial fibrillation with the 
risk of stroke. Although it is known that haemorrhage is a complication of 
anticoagulation use, overcoming the incidence of stroke remains a major goal (Sa et 
al., 2011).  
 
Now being developed is the research on the affectivity of the direct thrombin 
inhibitor as an alternative.  However, it will involve the age risk factor in the 
subpopulation of atrial fibrillation patients who are at risk of stroke, especially with 
liver insufficiency. That is due to the fact that direct thrombin inhibitors would be 
metabolized in the liver (Donnan et al., 2004). 
 
Warfarin has been shown to be highly effective in preventing stroke in the 
elderly with atrial fibrillation. However, the therapeutic index of warfarin is narrow. 
Bleeding complication may make the anticoagulation therapy difficult. In SPORTIF 
III and V trials, ximelagatran was reported as not inferior to warfarin, but it is 
recently declined in the market as it is found to contribute to higher rate of liver 
toxicity (Sellers & Newby, 2011). 
 
Individualized and closed monitoring should be performed in warfarin therapy 
to achieve the minimum therapeutic level. The rate of warfarin-related major 
bleeding is significantly higher in patients aged 75 years old and older than in 
younger patients. Intracranial haemorrhage is especially common in female patients 
over the age of 85 years. Therefore loading and maintenance need to be smaller than 
for the male (Sellers & Newby, 2011).  
 
21 
 
Atrial fibrillation significantly increases with age. Cardiac and/or non-cardiac 
(alcoholic, hyperthyroidism or pulmonary disease) co-morbidity are commonly 
associated with atrial fibrillation in the elderly. Warfarin management in elderly 
patients with atrial fibrillation should be prioritized first that involves the 
identification and correction of any precipitating and/or worsening factors for atrial 
fibrillation (Lee & Chen, 2008). 
 
The risk stratification needs to be confirmed for atrial fibrillation patients 
undergoing the anticoagulation therapy to ensure minimal risk of warfarin-related 
adverse effects such as thromboembolism and hemorrhagic complications. Optimal 
anticoagulation intensity needs to be controlled, and it is indexed using the INR. The 
INR value should fall within the therapeutic range. The value that is outside of the 
INR range will cause warfarin-related adverse reaction, which is either stroke or 
bleeding.  This means that the warfarin dose should exceed the minimum effect limit 
and that it should be maintained, not over the adverse effect limit (Peterson et al., 
1989).  
 
The stroke risk in patients with atrial fibrillation may be identified by using the 
risk stratification scheme. Various studies have been conducted to predict 
thromboembolism that is generally measured to predict stroke risk. Fang et al. (2007) 
revealed that these stratification schemes are the CHADS2 which functioned to score 
the factors of congestive heart failure, hypertension (high blood pressure), patient 
aged more than 75 years old, diabetes mellitus, stroke history and the SPORTIF 
(Stroke Prevention using an ORal Thrombin Inhibitor in Atrial Fibrillation) III and V 
trials.  
22 
 
Further investigation that supports the use of CHADS2 scheme has been done 
by Garcia et al. (2012), and it is suggested that the CHADS2 is applicable for stroke 
risk prediction. The CHADS2 scheme is also useful for recommending whether the 
antiplatelet or anticoagulation is better for stroke prevention in patients with atrial 
fibrillation. The CHADS2 scheme categorizes patients‟ stroke risk as low, moderate 
and high risks. However, based on the CHADS2 scores in their investigation on the 
use of oral anticoagulation used to prevent stroke, it was found that there is still a 
large percentage or specifically 50% of atrial fibrillation patients receiving oral 
anticoagulation in United States who failed to reach the desired outcome and in 
France 13% patients were even admitted due to the complications related to oral 
anticoagulation (Durham et al., 2010).  
 
 The inability to adhere to the intensive INR monitoring according to the 
guideline in older patients with supratherapeutic INR level will prolong the time of 
the outside therapeutic range. The supratherapeutic level of INR is common in older 
patients who received too high loading and maintenance warfarin dose, and it will 
delay return to the therapeutic range. For elderly patients, they usually have 
accommodation problems aside from transportation difficulty when they need to 
perform blood test to monitor the INR at the clinic. It is also difficult to contact some 
of them (Fang et al., 2007).  
 
The most common stroke occurred to patients who were admitted to hospital 
was due to untreated atrial fibrillation. Fortunately, stroke can be prevented, even for 
those who are at high risk (Panchal & Hussain, 2009). Increasing age, prior stroke, 
gastrointestinal bleeding (GI), hypertension, concurrent NSAID use, anaemia, renal 
impairment, neuropsychiatric disorder, and malignancy are related to the increase of 
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the risk of warfarin-associated adverse effect and hospitalization rates for intracranial 
and extra cranial bleeding. Polypharmacy and poor knowledge about anticoagulation 
have also been linked to haemorrhage (Fang et al., 2007). 
 
In 2006, Oden et al. recommended that high intensity anticoagulation 
associated with INR variability following initial warfarin administration and a 
moderate INR‟s intensity between 2.0–2.5 appear to provide optimal stroke 
prophylaxis and death in patients with atrial fibrillation. 
 
The incidence of stroke in patients with atrial fibrillation can be estimated by 
identifying the age factor. It was found that increasing age will also increase the risk 
of stroke. The research done by Wolf et al. (1991) has shown that atrial fibrillation is 
the only independent factor significantly associated with stroke; not hypertension, 
heart failure and coronary heart disease. 
 
1. 2 Problem Statement. 
 
In view of the effectiveness of warfarin as antithrombotic agent for patients 
with atrial fibrillations who are at high risk of stroke, the health professionals 
including pharmacists should be concerned about achieving better outcome of 
anticoagulation therapy.   
 
To achieve the goal, monitoring is absolutely needed to maintain the dose as 
warfarin has a narrow therapeutic index. An anticoagulation control has been 
performed but it was not systematically evaluated. To carry out their role, 
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pharmacists should really be concerned with the risk-benefit of warfarin therapy. The 
risk-benefit should be considered as a primary factor to determine the appropriate as 
well as the desired, therapeutic outcomes.  
 
The most important issue discussed in this study focuses on how the evaluation 
of the pharmacists‟ role in the multidisciplinary anticoagulation has been done.  Will 
the role of the pharmacist who focuses only on issues related to monitoring of 
warfarin able to improve the outcome of therapy and would it be more appropriate 
than expected? Factors such as the characteristics of patients‟ response that are 
related to the therapy should also be considered. 
 
Another important focus is to examine how patients respond to pharmacists‟ 
advices. Patients who are receiving warfarin are expected to comply with the 
pharmacist‟s instructions about dosage and consumption of food, herbs, supplements, 
and other drugs.  
 
 The Medication Therapy Adherence Clinic (Warfarin MTAC) is established in 
which pharmacists can play their important roles in the multidisciplinary team. It 
should be a great opportunity for the pharmacists to give contribution to obtain better 
outcome in patients‟ care. It is also to ensure that patients may get the benefit from 
the pharmacists‟ education on their medication therapy. Therefore, pharmacists 
should think and act appropriately in order to help the patients to improve better 
clinical endpoints. Pharmacists at the Warfarin MTAC play their roles to monitor 
warfarin medication and educate patients in order to reduce warfarin-related adverse 
effect. 
